OBJECTIVES: We compared the theoretical performance of a 1-time, birth cohort strategy with the currently recommended risk strategy for screening for hepatitis C virus (HCV) infection, which is undetected in an estimated 75% of 4 million affected people in the United States. METHODS: We applied current American Association for the Study of Liver Disease risk screening guidelines and a targeted birth cohort strategy to National Health and Nutrition Examination Survey data from 2003 to 2006 to estimate their performance in identifying HCV cases. RESULTS: Risk guidelines would recommend testing 25% of the US population aged 20 years or older and, if fully implemented, identify 82% of the projected HCV-exposed population. A targeted birth cohort (1946-1964) strategy would test 45% of the same population and identify 76% of the projected HCV population. CONCLUSIONS: In this ideal-world simulation, birth year and risk screening had similar theoretical performances for predicting HCV infection. However, actual implementation of risk screening has not achieved its theoretical performance, and birth cohort screening might increase HCV testing rates.
OBJECTIVES: We compared the theoretical performance of a 1-time, birth cohort strategy with the currently recommended risk strategy for screening for hepatitis C virus (HCV) infection, which is undetected in an estimated 75% of 4 million affected people in the United States. METHODS: We applied current American Association for the Study of Liver Disease risk screening guidelines and a targeted birth cohort strategy to National Health and Nutrition Examination Survey data from 2003 to 2006 to estimate their performance in identifying HCV cases. RESULTS: Risk guidelines would recommend testing 25% of the US population aged 20 years or older and, if fully implemented, identify 82% of the projected HCV-exposed population. A targeted birth cohort (1946-1964) strategy would test 45% of the same population and identify 76% of the projected HCV population. CONCLUSIONS: In this ideal-world simulation, birth year and risk screening had similar theoretical performances for predicting HCV infection. However, actual implementation of risk screening has not achieved its theoretical performance, and birth cohort screening might increase HCV testing rates.
Authors: M P Manns; J G McHutchison; S C Gordon; V K Rustgi; M Shiffman; R Reindollar; Z D Goodman; K Koury; M Ling; J K Albrecht Journal: Lancet Date: 2001-09-22 Impact factor: 79.321
Authors: Michael W Fried; Mitchell L Shiffman; K Rajender Reddy; Coleman Smith; George Marinos; Fernando L Gonçales; Dieter Häussinger; Moises Diago; Giampiero Carosi; Daniel Dhumeaux; Antonio Craxi; Amy Lin; Joseph Hoffman; Jian Yu Journal: N Engl J Med Date: 2002-09-26 Impact factor: 91.245
Authors: Bryce D Smith; Geoff A Beckett; Anthony Yartel; Deborah Holtzman; Nita Patel; John W Ward Journal: Am J Public Health Date: 2014-01-16 Impact factor: 9.308
Authors: A Brett Hauber; Brennan Mange; Mark A Price; Daniel Wolin; Mark Bensink; James A Kaye; David Chandler Journal: Support Care Cancer Date: 2017-08-07 Impact factor: 3.603
Authors: Scott W Biggins; Kiran M Bambha; Norah A Terrault; John Inadomi; Stephen Shiboski; Jennifer L Dodge; Jane Gralla; Hugo R Rosen; John P Roberts Journal: Liver Transpl Date: 2012-12 Impact factor: 5.799
Authors: Martin Zalesak; Kevin Francis; Alex Gedeon; John Gillis; Kyle Hvidsten; Phyllis Kidder; Hong Li; Derek Martyn; Leslie Orne; Amanda Smith; Ann Kwong Journal: PLoS One Date: 2013-05-21 Impact factor: 3.240